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Idiopathic pulmonary fibrosis (IPF) is a deadly disease, largely unresponsive to treatment
with corticosteroids and immunosuppressives. The aim of this randomized, prospective,
open-label study was to characterize the molecular effects of IFN-g-1b and colchicine, on
biomarkers expression associated with fibrosis (TGF-b, CTGF) and immunomodulatory/
antimicrobial activity (IFN-g), in the lungs of patients with IPF.
Fourteen (14) patients with an established diagnosis of IPF received either 200 mg of
IFN-g-1b subcutaneously three times per week, or 1mg of oral colchicine per day, for 24
months. Using RT-PCR assay, we evaluated the transcription levels of transforming growth
factor b1 (TGF-b1), connective-tissue growth factor (CTGF), and interferon-g (IFN-g) genes
in lung tissue before and after treatment with IFN-g-1b or colchicine.
Marked mRNA expression of TGF-b1 and CTGF, but complete lack of interferon-g was
detected in fibrotic lung tissue at entry. After treatment, both groups exhibited increased
expression of IFN-g gene at 6 months that was sustained at 24 months. The expression of
CTGF and TGF-b1 remained almost stable before and after treatment, in the IFN-g-1b
group, while TGF-b1 was statistically decreased after therapy, in the colchicine group
(p ¼ 0.0002). Significant difference in DLCO (% pred), was found between the two
treatment groups in favor of IFN-g-1b group (p ¼ 0.04). In addition, the IFN-g-1b group
showed stability in arterial PO2 while the colchicine group significantly deteriorated
(p ¼ 0.02).Elsevier Ltd. All rights reserved.
of Thoracic Medicine, Medical School, University of Crete, 71110 Heraklion, Crete, Greece.
0.
(N.M. Siafakas).
ARTICLE IN PRESS
Table 1 Demographics and lun
Median (range) age (yr)
Sex (Male/female)
FVC (%pred)
FEV1 (%pred)
TLC% (%pred)
DLCO, (%pred)
PaO2 (mmHg)

PaCO2 (mmHg)

Values are expressed as mean7SD
Breathing Room Air.
E.G. Tzortzaki et al.1822In conclusion, we report the effect of antifibrotic agents (IFN-g-1b and colchicine) in
TGF-b, CTGF, and endogenous IFN-g gene expression, in human fibrosis. However, extended
studies are needed to verify the pathophysiological consequences of these findings.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) belongs to the group of
idiopathic interstitial pneumonias (IIPs), leading to the
deposition of extracellular matrix and end-stage alveolar
fibrosis.1–4 The median survival of patients with IPF is 3–5
years after the onset of symptoms.5,6 Currently, two types of
therapeutic agents (anti-inflammatory and antifibrotic) have
been tested in the treatment of IPF.7,8 However, the disease
is largely unresponsive to treatment and no regimen has
been proven effective to improve survival or disease
progression.1,2
Molecular and cellular studies have identified several
growth factors involved in lung fibrosis and the production
and deposition of extracellular matrix proteins.9 Connective
tissue growth factor (CTGF) is a cysteine-rich peptide that
promotes proliferation, collagen synthesis, and chemotaxis
by mesenchymal cells. CTGF is over expressed in a variety of
fibrotic disorders, presumably secondary to the activation
and production of transforming growth factor-b.10 The
regulation of CTGF appears to be controlled primarily at
the level of transcription, and a brief exposure of fibroblasts
to transforming growth factor-beta (TGF-b) is sufficient to
induce a prolonged high level of CTGF expression. TGF-b
plays an important role in normal pulmonary morphogenesis
and function. TGF-b is involved in wound healing following
lung injury, being necessary for fibroblast proliferation,
stimulation of granulation, tissue formation, and collagen
deposition. It plays a key role in mediating fibrotic
tissue remodeling by increasing the production and decreas-
ing the degradation of connective tissue via several
mechanisms.10,11
Exogenous interferon gamma (IFN-g-1b), a cytokine highly
homologous with natural IFN-g is an attractive therapeutic
candidate in IPF, because it regulates both macrophage and
fibroblast functions. Therefore IFN-g may influence theg function tests of the study po
Group 1
IFN-g-1b (n ¼ 7)
66 (54–85)
6/1
80.7711.6
90.5714.7
73.1714.1
71.2719.8
80.075.8
40.573.6
, and age as median (range).course of IPF through its antimicrobial, antifibrotic, anti-
proliferative and immunomodulatory properties.7,12 The
therapeutic effectiveness of IFN-g-1b in IPF has been first
reported by Ziesche et al.,13 in a limited study. However,
Raghu et al.12 in a larger clinical trial failed to show a
beneficial effect on progression-free survival, pulmonary
function or the quality of life after one year of treatment.12
Colchicine is a well tolerated antifibrotic drug taken
orally, with multiple effects, including the arrest of cell
division, the inhibition of granulocytes migration, the
release of several proteins from cells, and the blocking of
the in vitro release of fibronectin from alveolar macro-
phages.14–16 Previous studies suggested that its effects in IPF
are similar to that of prednisone with fewer side effects,
while the median survival remained unchanged.14,15
The aim of this prospective, comparative trial was to
characterize molecular effects of subcutaneous IFN-g-1b
agent, versus conventional colchicine, after 6, 12, 24
months of therapy, on the transcription levels of TGF-b1,
CTGF and IFN-g biological markers, in 14 patients with IPF. In
this study we report the effect of antifibrotic agents
(IFN-g-1b and colchicine) in TGF-b, CTGF, and endogenous
IFN-g gene expression, in human lung fibrosis.Materials and methods
Study subjects
The study was approved by Medical Research Ethics
Committee of the Hospital and patients gave their written
informed consent. The enrolled patients were a subgroup
of a larger randomized controlled study including 50 IPF
patients.17
Fourteen (14) newly diagnosed, untreated, symptomatic
IPF patients with final histopathological diagnosis of IPF/UIPpulation at entry.
Group 2 p-value
Colchicine (n ¼ 7)
69 (42–82)
6/1
76.3719.8 0.5
88.1715 0.7
68.4711.1 0.4
57.2718.7 0.1
71.2713.4 0.1
40.171.3 0.8
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Effects of antifibrotic agents on TGF-b1, CTGF and IFN-g expression in patients with IPF 1823according to ERS/ATS Consensus Classification of the Idio-
pathic Interstitial Pneumonias criteria (2002), including
surgical lung biopsy, were included in this study.2 Eligible
patients were 40–75 years of age, had had clinical symptoms
of IPF for at least three months, and had a forced vital
capacity (FVC) X55% and p90% predicted value, a carbon
monoxide diffusing capacity (DLCO) that was at least 35
percent of the predicted value, and a PaO2 of more than
55mmHg while they were breathing air at rest (Table 1).
Criteria for exclusion were active infection within one week
before enrollment, unstable cardiovascular or neurological
disease, uncontrolled diabetes, pregnancy, lactation, or any
active malignancy.Study design
The study started with a run-in period of 2 months. During
the run-in period, all eligible patients received 50mg of oral
prednisolone per day for 4 weeks, with subsequent tapering
of the dose, over 1 month period, to 10mg per day. Then
patients were randomly assigned in 1:1 ratio to receive
either 200 mg of interferon gamma-1b, subcutaneously three
times per week, plus 10mg of oral prednisolone daily, or
1mg of oral colchicine per day, plus 10mg of oral
prednisolone daily. The duration of the treatment was
24-months. All new symptoms other than dyspnea were
recorded as adverse events. All patients were followed for
the duration of the study regardless of whether they
continued IFN-g-1b or colchicine. PFTs included spirometry,
measurement of FVC, TLC, DLCO, and arterial blood gases at
baseline and at 6, 12 and 16–24 months were measured
(Table 2).Biological material and RNA extraction
Two groups of patients were evaluated. The first consisted of
seven (7) patients treated with IFN-g-1b, and the second of
seven (7) patients treated with colchicine. For the assess-
ment of transforming growth factor b1 (TGF-b1), CTGF and
IFN-g transcription levels, open lung biopsies before, and
transbronchial-biopsies specimens after treatment were
obtained at 6 and 18–24 months interval. Samples were
frozen in liquid nitrogen and stored at 80 1C. Total RNA was
prepared separately from all patients at all three different
time points (0, 6 and 18–24 months). Total RNA was
extracted by using the RNeasy mini Kit (Qiagen Extraction
Kits, QIAGEN Inc., Valencia, CA, USA). The cDNA sequence of
the human TGF-b1, CTGF, IFN-g and the glyceraldehyde-3-
phosphate dehydrogenase (G3PDH) genes (GenBank Acces-Table 2 Pulmonary function at different time points in IFN-g-1
PATIENTS Interferon-g-1b group
Time-points Baseline
(7 pts)
6 months
(7 pts)
12 months
(7 pts)
24 mo
(6 pts)
FVC% pred 80.7711.6 80.576.8 83.077.7 83.17
TLC% pred 73.1714.1 69.1714.1 71.1710.3 67.57
TLCO% pred 71.2719.8 79.1719.1 75.1714.5 68.67
PO2 (mmHg) 80.075.8 79.779.7 80.174.7 74.57sion nos. NM_000660, NM_001901, J00219 and NM_002046)
were used to design primers for PCR amplification of the
corresponding cDNA fragments (Table 3). G3PDH gene served
as internal control. To this end, cDNA was synthesized by
using the QIAGEN OneStepRT-PCR Kit (QIAGEN Inc., Valencia,
CA, USA) from 2 mg of total RNA, using the reverse
transcriptase mix provided with the kit, as described by
the manufacturer. The mixture was incubated at 50 1C for
30min, reverse transcriptase was heat-inactivated and,
subsequently, the HotStartTaq DNA Polymerase (QIAGEN
Inc., Valencia, CA, USA) was activated by applying an initial
heating step at 95 1C for 15min. Therefore, cDNA was
amplified by the polymerase chain reaction (PCR) (40 cycles
of 94 1C for 30 s, 55 1C for 30 s, 72 1C for 1min, and finally
72 1C for 10min). Aliquots of PCR products were resolved by
agarose gel electrophoresis. The image was captured
using a Gel Doc digital imaging system (BioRad Gel Doc
2000 System, OH, USA) and analyzed with the BioRad
software (BioRad Inc., OH, USA). Relative quantities of
mRNAs among different patients were calculated from three
replicate RT-PCR experiments. Positive results were based
on the presence of DNA bands of the expected size (Table 3).Plasmid construction and sequencing
The cDNA sequence of the human interferon-g (IFN-g) gene,
generated by PCR, was purified by using the QIAquick PCR
Purification Kit (QIAGEN GmbH, Germany) and ligated into
the pGEM plasmid vector (Promega Corporation, USA). The
resultant plasmid was transformed into Escherichia coli JM
109 competent cells (Promega Corporation, USA) and the
confirmation of the construction was done by restriction
analysis (using the SalI and NcoI restriction sites of the
cloning vector) of several bacterial clones. Plasmid DNA was
isolated from these clones using QIAprep Spin Miniprep Kit
(QIAGEN GmbH, Germany). Restriction and DNA modification
enzymes were provided from MINOTECH (MINOTECH Bio-
technology, I.M.B.B.-FO.R.T.H., Heraklion, Crete, Greece)
and New England Biolabs Inc. For the amplified IFN-g
fragments both strands were completely sequenced accord-
ing to the di-deoxy-chain termination method following the
manufacturer protocol (Sequenase, USB), using vector
specific (T7, SP6) primers and the consensus nucleotide
sequence was obtained for two different treated patients,
from two sequencing reactions. A LiCor 4200L sequencer
(Lincoln, NE, USA) of the laboratory of Microchemistry
(IMBB-FORTH, Crete, Greece) was used. Restriction and
DNA modification enzymes were provided from MINOTECHb and colchicine treated group.
Colchicine group
nths Baseline
(7 pts)
6 months
(7 pts)
12 months
(7 pts)
24 months
(2 pts)
8.1 76.3719.8 69.2715.2 63.0714.9 69.077.0
10.8 68.4711.1 60.075.7 58.579.4 53.0724.0
14.6 57.2718.7 57.0710.7 56.0714.0 59.0726.8
10.2 71.2713.4 67.1712.6 62.8711.1 65.576.3
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E.G. Tzortzaki et al.1824(MINOTECH Biotechnology, I.M.B.B.-FO.R.T.H., Heraklion,
Crete, Greece) and New England Biolabs.
Quantification of signal intensity
RT-PCR gel images were analyzed with the Scion Image for
Windows software (Scion, Fredrick, MD, USA), available free
at http://www.scioncorp.com and at http://rsb.info.nih.
gov/nih-image/, using standard protocols.18,19 The resulting
measurements were exported to an Excel spreadsheet for
quantification. Bar graphs for data representing quantifica-
tion of signal intensities (arbitrary units) of the transcription
levels of G3PDH, TGF-b, CTGF and IFN-g mRNAs in lung
tissue, at different time points (0, 6, 12, 18–24 months)
after therapy, in both groups, were employed (Figs. 2
and 4).
Statistical analysis
The statistical analysis was carried out using the SPSS
software, version 8.0 (SPSS Inc., Chicago IL, USA). Compar-
isons between and within groups were made using unpaired
t-test, paired t-test, Mann–Whitney U tests or chi-squared
statistics as appropriate. Comparisons for PFTs (FVC, TLC,
DLCO) and PO2 in each time point were made by ANCOVA test
for repeated measurements. A p-value of 0.05 or less was
considered statistically significant.
Results
Fourteen patients were included in the study and underwent
randomization (1 to 1) to receive either 200 mg of interferonFigure 1 mRNA expression of TGF-b1, CTGF, INF-g, before and afte
the DNA ladder used.gamma-1b subcutaneously three times per week, or 1mg of
oral colchicine per day; 7 patients received IFN-g-1b and 7
colchicine. The majority of patients were male, the median
age was 66 (median range 54–85), in the IFN-g-1b group, and
69 (median range 42–82), in the colchicine group. Baseline
demographics characteristics among the two groups are
presented in Table 2.Effects of IFN-c-1b and colchicine on the
transcription of TGF-b1, CTGF and IFN-c genes
The molecular effects of IFN-g-1b agent in IPF, the
transcription of TGF-b1, CTGF and IFN-g genes in lung tissue
are shown in Fig. 1. Before treatment, all patients exhibited
marked mRNA expression of TGF-b1 and CTGF, but not IFN-g
(Fig. 2a). The expression of TGF-b1 remained almost stable
after treatment, in the IFN-g-1b group (Fig. 2b and c). Four
out of seven patients showed transcription of IFN-g gene at 6
(1 patient) and at 18–24 (3 patients) months after treatment
(Fig. 2b and c). The expression of CTGF gene remained
almost stable (non-noticeable differences) before and after
treatment (Fig. 1). The transcription of G3PDH gene (served
as internal control) was constitutively expressed before and
after treatment (Fig. 1). This observation indicated that
IFN-g-1b agent enhanced the expression of the patients’
endogenous gene. Moreover, no significant difference in the
intensity of G3PDH was observed between treated and non-
treated patients, a finding that indicates that IFN-g-1b does
not affect the stability of the relevant mRNAs.
The effect of colchicine treatment is shown in Fig. 3.
After colchicine treatment three out of seven patients
presented increased expression of IFN-g mRNA (Fig. 3). The
expression of CTGF gene remained almost stable before andr treatment with IFN-g-1b. The insert in the right corner pictures
ARTICLE IN PRESS
Figure 2 Bar graphs representing quantification of signal intensities (arbitrary units) for TGF-b1, CTGF and IFN-g mRNAs before (a)
and after (b, c) IFN-g-1b treatment. * p-valueo0.05.
Figure 3 mRNA expression of TGF-b1, CTGF, INF-g, before and after treatment with colchicine. The insert in the right corner
pictures the DNA ladder used.
Effects of antifibrotic agents on TGF-b1, CTGF and IFN-g expression in patients with IPF 1825after treatment while the transcription of TGF-b1 was
decreased (p ¼ 0.0002) after therapy (Fig. 4a and b). The
expression of G3PDH housekeeping gene remained stable
before and after treatment with colchicine (Fig. 4).
In summary, the transcription of the IFN-g gene was
clearly upregulated in both groups of patients receiving
either IFN-g-1b or colchicine, indicating that both agents
may induce the expression of the endogenous IFN-g.Cloning of the human interferon-c gene
The high levels of IFN-g gene transcription in both groups of
patients (Figs. 2b, c and 4b), after treatment, prompted us
to test whether the IFN-g bands represented an authenticcDNA product rather than being an artificially amplified PCR
product of the same size of IFN-g. To this end, and because
of the very limited amount of the RT-PCR product, cDNAs
were cloned and 6 positive clones were sequenced for both
groups of IPF patients. The nucleotide sequences deter-
mined were identical to the published sequence of human
IFN-g, thus ensuring us that the therapeutic agents used
really induced the expression of the IFN-g gene (Figs. 5
and 6).Pulmonary function tests (PFTs):
Comparisons in PFTs (FVC, TLC, DLCO) and PO2 between
groups were made using unpaired test, paired t-test,
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Figure 4 Bar graphs representing quantification of signal intensities (arbitrary units) for TGF-b1, CTGF and IFN-g mRNAs before
(a) and after (b) colchine treatment. * p-valueo0.05.
Figure 5 Sequencing of IFN-g gene in a IFN-gamma treated IPF patient. A1 and A2 show sequencing results of IFN-g gene within T7
forward promoter of pGEM-T Vector. B1 and B2 show sequencing results of IFN-g gene within SP6 reverse promoter of pGEM-T Vector.
Green braces and arrows show pGEM-T Vector sequence, and red braces show the IFN-g gene sequence.
E.G. Tzortzaki et al.1826Mann–Whitney U tests or chi-squared statistics as appro-
priate, and comparisons in PFTs within groups in each time
point were made by ANCOVA test for repeated measure-ments. Significant difference in DLCO (% pred), was found
between the two treatment groups (mean+SD, 71.2+19.8 to
75.1+14.5 in IFN-g patients versus 57.2+18.7 to 56.0+14.0 in
ARTICLE IN PRESS
Figure 6 Sequencing of IFN-g gene in a colchicine treated IPF patient. A1 and A2 show sequencing results of IFN-g gene within T7
forward promoter of pGEM-T Vector. B1 and B2 show sequencing results of IFN-g gene within SP6 reverse promoter of pGEM-T Vector.
Green braces and arrows show pGEM-T Vector sequence, and red braces show the IFN-g gene sequence.
Table 3 Sequence of PCR primers and internal control, the product size and the GenBank Accession number of each gene
studied.
Gene Upstream primer Downstream primer Product size GenBank
TGF-b1 50-GCCCTGGACACCAACTATTGC-30 50-AGGCTCCAAATGTAGGGGCAG-30 161 NM_000660
CTGF 50-CCGACTGGAAGACACGTTTGG-30 50-TCATGCCATGTCTCCGTACATCTT-30 505 NM_001901
IFN-g 50-GCATCGTTTTGGGTTCTCTTGGCTGTTACTGC-30 50-CTCCTTTTTCGCTTCCCTGTTTTAGCTGCTGG-30 427 J00219
G3PDH 50-GGGGAAGGTGAAGGTCGGAGT-30 50-TTGGAGGCCATGTGGGCCAT-30 999 NM_002046
Effects of antifibrotic agents on TGF-b1, CTGF and IFN-g expression in patients with IPF 1827colchicine patients, p ¼ 0.04) at three different time points
(baseline, 6 and 12 months) in favour of IFN-g-1b group
(Table 2). The IFN-g-1b group showed stability in arterial PO2
(mean+SD, 80+5.8 to 80.1+4.7, p ¼ NS) while the colchicine
group significantly deteriorated (71.2+13.4 to 62.8+11.1,
p ¼ 0.02). No differences were detected for FVC% pred,
TLC% pred and DLCO within both treatment groups over time
(Table 2).Discussion
To our knowledge this is the first study to report the effect of
IFN-g-1b versus colchicine on specific biomarkers expression(TGF-b, CTGF, IFN-g), in a well defined population of IPF/UIP
patients. Fourteen newly diagnosed, untreated, patients with
final histopathological diagnosis of IPF/UIP according to ERS/
ATS Consensus Classification of the Idiopathic Interstitial
Pneumonias criteria,2 with surgical lung biopsy, were in-
cluded. Multiple transbronchial-biopsies specimens (3 biopsies
each from the right, middle, and lower lobes) were further
obtained at 6 and 18–24 months interval, after therapy.
A concern could be that pre- and post-treatment lung biopsies
were delivered by different methods. However, recent studies
in the literature20 suggest that characteristic histologic
features of UIP can be identified on transbronchial biopsies
specimens and TBB may be more useful in UIP than previously
recognized.20 Moreover, in this study, a pathologist (A.V.K.)
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E.G. Tzortzaki et al.1828evaluated the transbronchial-biopsies specimens. All samples
were adequate, containing features considered diagnostic of
UIP (the typical patchwork pattern of interstitial fibrosis with
alternating areas of interstitial fibrosis and normal alveolar
septa).
Marked mRNA expression of TGF-b1, but no transcription
of IFN-g mRNA was detected in fibrotic lung tissue before
therapy. The expression of CTGF gene remained almost
stable before and after treatment while the transcription of
TGF-b1 was statistically decreased (p ¼ 0.0002) after 6
months of therapy, only in the colchicine group. Colchicine
is a potent in vitro inhibitor of fibroblast functions in terms
of proliferation and collagen synthesis.21 On the other hand,
although colchicine is known to inhibit many leukocyte
functions, it is a poor inhibitor of cytokines known to be
important for fibrogenesis (e.g. IL-6, TNF-alpha, IL-1), as
concluded from in vitro studies.21,22 After treatment, both
groups exhibited increased expression of IFN-g gene at 6
months, finding that was sustained at 24 months in the IFN-
g-1b group. A third transbronchial biopsy after 18–24 months
of treatment was performed in the IFN-g-1b group in order
to see any significant over time changes in the mRNA levels
of TGF-b1, CTGF and IFN-g genes. Unfortunately, this
practice was not possible for the colchicine group since
two patients died within twelve months of therapy and the
rest did not consent.
The overall molecular analysis did not show any consistent
effect of IFN-g-1b treatment on mRNA expression of TGF-b1
or CTGF, which are in accordance with the recent report by
Strieter et al.23 but in contrast to Ziesche et al.13 findings.
Lack of effect on transcription levels of those profibrotic
cytokines in the IFN-g-1b group, however, does not negate
preclinical data showing that IFN-g modifies collagen
synthesis by human lung fibroblasts through other path-
ways.23,24 A current hypothesis proposes that the aberrant
neovascularization that occurs in pulmonary fibrosis results
from the imbalance of angiogenic versus angiostatic CXC
chemokines.25 Recently, Strieter et al.23 in a randomized
double-blind placebo-controlled trial with 32 IPF patients
supported that IFN-g upregulates molecules associated with
antimicrobial defence and antiangiogenesis. Changes in
angiogenic/angiostatic cytokines after 6 months treatment
with IFN-g-1b, as compared with placebo, suggest beneficial
effects of IFN-g-1b on the process of fibrosis.23 Strieter
et al.23 findings could provide a basis for the results from a
large clinical trial consisted of 330 IPF patients in which a
trend toward prolonged survival was observed in IFN-g-1b
treated group.12
However, our findings could not be comparable with
previous studies,13,23 because of differences in the study
population and/or study design. Firstly, Ziesche’s results13
have been revaluated and it has been demonstrated that
only some of the patients included, were IPF patients.26,27
Secondly, we performed this study using the VATS biopsy as
baseline tissue sample, while Strieter et al.23 have used the
transbronchial biopsies in two different time points. To the
best of our knowledge, our study is the first to result long-
term effects of two different treatment arms in a well-
defined IPF/UIP population and it is complementary in the
current experience in this field.13,23
Another treatment strategy might propose the adminis-
tration of IFN-g-1b as a promoter of T helper 1 (Th1)response which facilitates cell-mediated immunity, de-
creases fibroblast proliferation and angiogenesis and pro-
motes restoration.25 Interleukin-18 (IL-18) has been
identified as an interferon-gamma (IFN-g) mediator, promot-
ing a Th1 response. Th1 response is characterized by
increased expression of IFN-g, interleukin-12 (IL-12) and
interleukin-18 (IL-18). In this context, we have measured
the levels of IL-12 and IL-18, in the bronchoalveolar lavage
fluid (BALF) in a subgroup of 10 IPF/UIP patients, participat-
ing in this study, before and after 6 months of treatment
with IFN-g-1b (5 patients) or colchicine (5 patients).28 BALF
IL-18 levels were significantly decreased after treatment
with IFN-g-1b (po0.05). A significant difference was also
found after treatment with colchicine (po0.01). A signifi-
cant correlation was found between IL-18 BALF levels and
the BALF neutrophils (r ¼ 0.75, p ¼ 0.024). Our data
suggested the potential role of IL-18 as an inflammatory
marker in the pathogenetic pathway of IPF.28
An additional finding of our study is the significant
difference of DLCO (%pred) and pO2 in favor of IFN-g-1b
treatment after 12 months of treatment. For DLCO (%pred)
this difference was obvious even after 6 months of therapy.
A similar trend has been reported by Strieter et al.23 in the
IFN-g-1b group for gas exchange and for FEV1 after six
months of treatment.23 In addition, a statistical significant
difference has been detected in FVC (%pred) in favour of IFN
gamma group after two years of treatment in 50 IPF patients
in a prospective randomized study.17 However, smaller
studies of IFN-g therapy in IPF have shown controversial
results. Kalra et al.29 observed symptomatic and functional
improvement only in one of the 21 patients treated.
Similarly, Prasse et al.30 found improvement in PFTs only in
one among five patients. In contrast, Nathan et al. reported
that, paradoxically, patients with advanced disease appear
to derive the most benefit from IFN-g therapy.31
In conclusion, our data showed that the transcription of
the IFN-g gene was clearly upregulated in both groups of
IPF/UIP patients, indicating that IFN-g-1b is effective at
least, as well as conventional colchicine, in inducing the
expression of the endogenous IFN-g. Moreover, IFN-g-1b
treatment could improve outcome and survival in a well-
defined population of IPF patients if given early and for long
period of time.17,30,32,33 These results suggested that
systemic administration of IFN-g could favorably affect
various biological pathways in IPF patients. However,
extended studies are needed.Acknowledgments
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